HLS Historical Financial Ratios
| HLS Stock | CAD 3.65 0.15 4.29% |
HLS Therapeutics is recently reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 0.82 or Days Sales Outstanding of 42.74 will help investors to properly organize and evaluate HLS Therapeutics financial condition quickly.
HLS |
About HLS Financial Ratios Analysis
HLS TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate HLS Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on HLS financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across HLS Therapeutics history.
HLS Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing HLS Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on HLS Therapeutics sales, a figure that is much harder to manipulate than other HLS Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Dividend Yield
Dividend Yield is HLS Therapeutics dividend as a percentage of HLS Therapeutics stock price. HLS Therapeutics dividend yield is a measure of HLS Therapeutics stock productivity, which can be interpreted as interest rate earned on an HLS Therapeutics investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to HLS Therapeutics. There are two different methods for calculating HLS Therapeutics invested capital: operating approach and financing approach. Understanding HLS Therapeutics invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Return On Assets
A profitability ratio that indicates the percentage of profit a company earns in relation to its overall resources. It is calculated by dividing net income by total assets.Most ratios from HLS Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into HLS Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HLS Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, HLS Therapeutics' Days Payables Outstanding is very stable compared to the past year. As of the 13th of December 2024, EV To Operating Cash Flow is likely to grow to 12.61, while Price To Sales Ratio is likely to drop 1.22.
| 2021 | 2022 | 2023 | 2024 (projected) | Dividend Yield | 0.0137 | 0.0203 | 0.0194 | 0.0102 | Price To Sales Ratio | 6.19 | 3.83 | 1.96 | 1.22 |
HLS Therapeutics fundamentals Correlations
Click cells to compare fundamentals
HLS Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
HLS Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 10.29 | 7.83 | 6.19 | 3.83 | 1.96 | 1.22 | |
| Dividend Yield | 0.007955 | 0.0114 | 0.0137 | 0.0203 | 0.0194 | 0.0102 | |
| Ptb Ratio | 3.13 | 2.59 | 2.31 | 1.88 | 1.27 | 0.82 | |
| Days Sales Outstanding | 79.91 | 81.3 | 59.43 | 52.88 | 61.88 | 42.74 | |
| Book Value Per Share | 6.07 | 5.34 | 4.99 | 3.86 | 3.03 | 1.95 | |
| Free Cash Flow Yield | 0.0428 | (0.0805) | 0.0321 | 0.0289 | 0.13 | 0.12 | |
| Stock Based Compensation To Revenue | 0.0694 | 0.0451 | 0.0392 | 0.0475 | (0.00853) | (0.008103) | |
| Capex To Depreciation | 0.0241 | 0.0787 | 1.35 | 0.15 | 0.005811 | 0.00552 | |
| Pb Ratio | 3.13 | 2.59 | 2.31 | 1.88 | 1.27 | 0.82 | |
| Ev To Sales | 11.14 | 9.37 | 7.46 | 5.07 | 3.01 | 1.69 | |
| Free Cash Flow Per Share | 0.81 | (1.11) | 0.37 | 0.21 | 0.48 | 0.51 | |
| Roic | (0.0164) | (0.041) | (0.0272) | (0.0603) | (0.0556) | (0.0528) | |
| Inventory Turnover | 0.94 | 0.34 | 0.45 | 0.56 | 0.8 | 0.76 | |
| Net Income Per Share | (0.67) | (0.48) | (0.41) | (0.73) | (0.85) | (0.81) | |
| Days Of Inventory On Hand | 388.24 | 1.1K | 820.15 | 652.32 | 456.44 | 479.26 | |
| Payables Turnover | 0.21 | 0.14 | 0.39 | 0.43 | 0.54 | 0.51 | |
| Sales General And Administrative To Revenue | 0.16 | 0.24 | 0.33 | 0.29 | 0.13 | 0.18 | |
| Capex To Revenue | 0.0472 | 0.8 | 0.0752 | 0.17 | 0.002996 | 0.002847 | |
| Cash Per Share | 0.41 | 1.6 | 0.65 | 0.66 | 0.64 | 0.58 | |
| Pocfratio | 21.1 | 46.99 | 22.61 | 13.88 | 7.85 | 8.24 | |
| Interest Coverage | (0.6) | (1.92) | (0.9) | (1.84) | (1.18) | (1.12) | |
| Payout Ratio | (0.23) | (0.33) | (0.39) | (0.2) | (0.0871) | (0.0915) | |
| Capex To Operating Cash Flow | 0.0969 | 4.78 | 0.27 | 0.6 | 0.012 | 0.0126 | |
| Pfcf Ratio | 23.37 | (12.43) | 31.16 | 34.61 | 7.94 | 8.34 | |
| Days Payables Outstanding | 2.5K | 924.53 | 856.08 | 849.37 | 675.37 | 709.14 | |
| Income Quality | (1.35) | (0.61) | (1.25) | (0.72) | (0.57) | (0.6) | |
| Roe | (0.11) | (0.0906) | (0.0816) | (0.19) | (0.28) | (0.27) | |
| Ev To Operating Cash Flow | 22.84 | 56.25 | 27.26 | 18.4 | 12.01 | 12.61 | |
| Pe Ratio | (28.5) | (28.64) | (28.31) | (9.96) | (4.5) | (4.73) | |
| Return On Tangible Assets | (0.29) | (0.3) | (0.28) | (0.51) | (0.59) | (0.56) | |
| Ev To Free Cash Flow | 25.3 | (14.88) | 37.57 | 45.89 | 12.15 | 12.76 | |
| Earnings Yield | (0.0351) | (0.0349) | (0.0353) | (0.1) | (0.22) | (0.21) | |
| Intangibles To Total Assets | 0.81 | 0.88 | 0.79 | 0.83 | 0.78 | 1.43 | |
| Current Ratio | 1.34 | 1.29 | 1.58 | 1.42 | 1.65 | 1.57 | |
| Tangible Book Value Per Share | (2.52) | (2.65) | (2.13) | (2.15) | (2.0) | (2.1) | |
| Receivables Turnover | 4.57 | 4.49 | 6.14 | 6.9 | 5.9 | 5.6 |
Pair Trading with HLS Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.
The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in HLS Stock
HLS TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate HLS Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on HLS financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across HLS Therapeutics history.